Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?

Madjd Z, Durrant LG, Pinder SE, Ellis IO, Ronan J, Lewis S, Rushmere NK, Spendlove I.

Cancer Immunol Immunother. 2005 Feb;54(2):149-56. Epub 2004 Sep 16.

PMID:
15378282
2.
3.

Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.

Schmitt CA, Schwaeble W, Wittig BM, Meyer zum Büschenfelde KH, Dippold WG.

Eur J Cancer. 1999 Jan;35(1):117-24.

PMID:
10211099
4.
5.

Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.

Liu M, Yang YJ, Zheng H, Zhong XR, Wang Y, Wang Z, Wang YG, Wang YP.

Oncol Rep. 2014 Dec;32(6):2619-27. doi: 10.3892/or.2014.3496. Epub 2014 Sep 18.

PMID:
25241923
6.

Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.

Gorter A, Blok VT, Haasnoot WH, Ensink NG, Daha MR, Fleuren GJ.

Lab Invest. 1996 Jun;74(6):1039-49.

PMID:
8667608
7.

Loss of CD59 expression in breast tumours correlates with poor survival.

Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J, Durrant LG.

J Pathol. 2003 Aug;200(5):633-9.

PMID:
12898600
8.

Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma.

Shimo K, Mizuno M, Nasu J, Hiraoka S, Makidono C, Okazaki H, Yamamoto K, Okada H, Fujita T, Shiratori Y.

J Gastroenterol Hepatol. 2004 Jun;19(6):643-7.

PMID:
15151618
9.

Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer.

Rushmere NK, Knowlden JM, Gee JM, Harper ME, Robertson JF, Morgan BP, Nicholson RI.

Int J Cancer. 2004 Mar 1;108(6):930-6.

10.

Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer.

Shang Y, Chai N, Gu Y, Ding L, Yang Y, Zhou J, Ren G, Hao X, Fan D, Wu K, Nie Y.

Arch Pathol Lab Med. 2014 Jul;138(7):910-9. doi: 10.5858/arpa.2013-0064-OA.

PMID:
24978917
11.

Differential expression of the complement regulatory proteins in the human eye.

Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ.

Invest Ophthalmol Vis Sci. 1993 Dec;34(13):3579-84.

PMID:
7505007
14.

Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.

Goslings WR, Blom DJ, de Waard-Siebinga I, van Beelen E, Claas FH, Jager MJ, Gorter A.

Invest Ophthalmol Vis Sci. 1996 Aug;37(9):1884-91.

PMID:
8759358
15.

Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes.

Christmas SE, de la Mata Espinosa CT, Halliday D, Buxton CA, Cummerson JA, Johnson PM.

Immunology. 2006 Dec;119(4):522-8. Epub 2006 Sep 26.

16.

Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.

Ravindranath NM, Shuler C.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Feb;103(2):231-9. Epub 2006 Oct 16.

PMID:
17234541
17.

Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.

Brasoveanu LI, Altomonte M, Fonsatti E, Colizzi F, Coral S, Nicotra MR, Cattarossi I, Cattelan A, Natali PG, Maio M.

Lab Invest. 1996 Jan;74(1):33-42.

PMID:
8569195
18.
19.

Loss of CD55 is associated with aggressive breast tumors.

Madjd Z, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE.

Clin Cancer Res. 2004 Apr 15;10(8):2797-803.

20.

Supplemental Content

Support Center